Treatment of short bowel syndrome patients with colon-in-continuity
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
1. A method of treating a patient having short bowel syndrome with elevated basal levels of endogenous GLP-2 (as compared to a normal healthy individual), who receives parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to reduce or eliminate said weekly parenteral nutrition received by said patient.
2. The method of claim 1 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 μg/kg.
3. The method of claim 2 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg.
4. The method of claim 1 , wherein the [Gly2]hGLP-2 is administered by subcutaneous injection.
5. The method of claim 4 , wherein the subcutaneous injection is into the abdomen, thigh, or arm.
6. The method of claim 1 , wherein the patient is an adult.
7. A method of treating a patient having short bowel syndrome with elevated basal levels of endogenous GLP-2 (as compared to a normal healthy individual), who receives parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to increase wet weight absorption compared to a baseline wet weight absorption by said patient.
8. The method of claim 7 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 μg/kg.
9. The method of claim 8 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg.
10. The method of claim 7 , wherein the [Gly2]hGLP-2 is administered by subcutaneous injection.
11. The method of claim 10 , wherein the subcutaneous injection is into the abdomen, thigh, or arm.
12. The method of claim 7 , wherein the patient is an adult.
13. A method for treating a patient having short bowel syndrome with elevated basal levels of endogenous GLP-2 (as compared to a normal healthy individual) and who is dependent on parenteral nutrition, said method comprising administering to the said patient [Gly2]hGLP-2 using a dosing regimen effective to enhance intestinal absorption by said patient.
14. The method of claim 13 , wherein the GLP-2 receptor agonist is administered at a daily dose of from 5 to 500 μg/kg.
15. The method of claim 14 , wherein the GLP-2 receptor agonist is administered at a daily dose of from 30 to 150 μg/kg.
16. The method of claim 13 , wherein the GLP-2 receptor agonist is administered by subcutaneous injection.
17. The method of claim 16 , wherein the subcutaneous injection is into the abdomen, thigh, or arm.
18. The method of claim 13 , wherein the intestinal absorption is enhanced by an increase in wet weight absorption of at least 750 mL/day compared to a baseline wet weight absorption.
19. The method of claim 13 , wherein the patient is an adult.
20. The method of claim 1 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days.
21. The method of claim 7 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days.
22. The method of claim 13 , wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days.
23. The method of claim 1 , wherein the parenteral nutrition is reduced by volume or frequency of administration.
24. The method of claim 1 , wherein said patient is an adult and the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.
25. The method of claim 7 , wherein said patient is an adult and the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.
26. The method of claim 13 , wherein said patient is an adult and the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg by subcutaneous injection.